Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL Zanubrutinib versus bendamustine and rituximab in untreated patients with CLL/SLL February 2025 Clinical trials Read more
2022 September Pharma News FDA grants priority review to novel haemophilia A treatment efanesoctocog alfa Read more
2022 September Clinical trials FDA approves pemigatinib for myeloid/lymphoid neoplasms patients with altered FGFR Read more
2022 September Health Innovation Wearable device for tracking temperature of paediatric blood cancer patients at home Read more
2022 August Clinical practice Combination maintenance therapy improves survival in TP53-deficient AML post-HSCT Read more
2022 August Pharma News Autologous cell therapy shows clinical benefits for multiple myeloma patients Read more
2022 August Clinical practice Study reviews scope of improvements in neonatal intensive care for anaemic babies Read more
Top
